Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 700 Breast Neoplasms 630 Neoplasms 583 Leukemia, Myeloid, Acute 481 Colorectal Neoplasms 457 Multiple Myeloma 444 Melanoma 426 Prostatic Neoplasms 383 Neoplasm Metastasis 374 Pancreatic Neoplasms 364 Recurrence 350 Lymphoma 340 Ovarian Neoplasms 325 Lung Neoplasms 298 Lymphoma, Non-Hodgkin 295 Leukemia 287 Glioblastoma 276 Precursor Cell Lymphoblastic Leukemia-Lymphoma 249 Stomach Neoplasms 246 Leukemia, Lymphocytic, Chronic, B-Cell 235 Carcinoma, Hepatocellular 231 Squamous Cell Carcinoma of Head and Neck 220 Lymphoma, Large B-Cell, Diffuse 217 Myelodysplastic Syndromes 212 Carcinoma, Renal Cell 210 Lymphoma, Follicular 183 Head and Neck Neoplasms 172 Brain Neoplasms 169 Lymphoma, Mantle-Cell 167 Triple Negative Breast Neoplasms 166

Interventions

glembatumumab vedotin 1 CR011-vcMMAE 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Squamous Cell Carcinoma of the Lung × Clear all

NCT02713828 2019-07-16

PrE0504

PrECOG, LLC.

Phase 1/2 Terminated

13 enrolled 12 charts

Squamous Cell Carcinoma of the Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡